Gennex Laboratories Limited (531739) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Gennex Laboratories Limited ₹27.82, price ₹9.80, upside +183.9%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Gennex Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹4.99 – ₹27.87 · fair‑value band ₹20.86 – ₹34.77 · the ₹9.80 price screens below the ₹27.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Gennex Laboratories in your weekly email
Every Wednesday you see whether Gennex Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole.
Show more
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Stock analysis
Gennex Laboratories Limited (531739) currently trades at ₹9.80, while our model-based Fair Value estimate is ₹27.82, implying the stock looks roughly 64.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹46.87 per share, and 15 of the 15 models we run sit above the ₹9.80 price.
Bear case: the Economic Profit group reads lowest at ₹11.39, and 0 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹20.86 (bear) to ₹34.77 (bull), the price of ₹9.80 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Gennex Laboratories Limited reported revenue of ₹1.7B in FY2026 versus ₹612M in FY2022, a compound +29.6%/yr. Reported net income was ₹210M in FY2026, compounding +52.1%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹473M (≈ $4.9M) · P/E ratio 32.2 · P/S ratio 3.91 · EPS (TTM) ₹0.1130 · Net margin 12.1% · Return on assets (EBIT) 5.5% · Operating margin 4.3% · Revenue growth (YoY) −19.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 184%, 531739 screens cheaper than that median.
Fair Value models
Bear ₹20.86Fair Value ₹27.82Bull ₹34.77
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.0576 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+25.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
Start year 2021 (pandemic). Over 10 years: +16.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.9% vs 15.5%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 12%
Compare Gennex Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2432 stocks
Beats the sector median on 1/9 measures
Overall it trails its sector peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside+47.9% · Top 25%
Profitability
Return on assets0.0% · Below median
Net margin (TTM)2.7% · Below median
Operating margin (TTM)4.3% · Below median
Growth and dividend
Revenue growth−19.7% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gennex Laboratories Limited (531739) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹27.82 versus a price of ₹9.80, about +184% upside (undervalued).
What is the fair value of 531739?
Our model-based fair value for Gennex Laboratories Limited is ₹27.82 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹9.80.
What is the quality score of 531739?
Gennex Laboratories Limited has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gennex Laboratories Limited (531739)?
Our model-based price target is the fair value of ₹27.82 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario ₹20.86, optimistic scenario ₹34.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Gennex Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹27.82, about +184% upside versus a price of ₹9.80 (undervalued). Cautious scenario ₹20.86, optimistic scenario ₹34.77. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Gennex Laboratories Limited (531739)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gennex Laboratories Limited it is ₹27.82 per share (as of Sep 24, 2026), against a price of ₹9.80. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Gennex Laboratories Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 531739 trades below its calculated fair value: price ₹9.80, fair value ₹27.82, a gap of about +184% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531739?
No. The price is what the market pays today (₹9.80); the fair value is what the company's own numbers justify (₹27.82). For Gennex Laboratories Limited the two are ₹18.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gennex Laboratories Limited worth?
The market values Gennex Laboratories Limited at about ₹473M (market capitalisation, as of Sep 24, 2026). Per share that is ₹9.80; our models calculate a fair value of ₹27.82 per share.
What do the bullish and bearish scenarios say about 531739?
Our models span a range for Gennex Laboratories Limited: cautious scenario ₹20.86, base ₹27.82, optimistic ₹34.77 per share (as of Sep 24, 2026, price ₹9.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 531739?
Gennex Laboratories Limited trades at a price-to-earnings ratio of 32.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹27.82 is built from several models across several years.
How solid is the balance sheet of Gennex Laboratories Limited (531739)?
Balance-sheet figures for Gennex Laboratories Limited (as of Sep 24, 2026): debt of 0.20 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 531739 from its 52-week high?
Gennex Laboratories Limited trades at ₹9.80, about 42% below its 52-week high of ₹17.02 and 37% above the low of ₹7.13 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹27.82 is for.
Which stocks are comparable to Gennex Laboratories Limited?
From the same area (Healthcare) we also value Anuh Pharma Limited, Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gennex Laboratories Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹9.80, calculated fair value ₹27.82 (+184%), Quality Score 25/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531739 calculated?
We run Gennex Laboratories Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹27.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gennex Laboratories Limited currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gennex Laboratories Limited (531739)?
The closing price on Oct 1, 2026 was ₹9.80. Our model-based fair value is ₹27.82, about +184% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gennex Laboratories Limited right now?
The large discount to fair value meets weak quality (25/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹20.86). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Gennex Laboratories Limited
How large is the market capitalisation of Gennex Laboratories Limited (531739)?
The market capitalisation of Gennex Laboratories Limited is ₹473M (≈ $4.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gennex Laboratories Limited (531739)?
The price-to-sales ratio of Gennex Laboratories Limited is 3.91 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gennex Laboratories Limited (531739)?
Earnings per share at Gennex Laboratories Limited are ₹0.1130 (price ÷ EPS = P/E 32.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gennex Laboratories Limited (531739)?
The net margin of Gennex Laboratories Limited is 12.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Gennex Laboratories Limited (531739)?
On an EBIT basis the return on assets of Gennex Laboratories Limited is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gennex Laboratories Limited (531739)?
The operating margin of Gennex Laboratories Limited is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gennex Laboratories Limited (531739)?
Revenue at Gennex Laboratories Limited is growing −19.7% versus a year earlier (3y avg +38.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gennex Laboratories Limited (531739)?
Earnings per share at Gennex Laboratories Limited are growing −53.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gennex Laboratories Limited (531739) generate?
The free cash flow of Gennex Laboratories Limited is −₹756M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gennex Laboratories Limited (531739) carry?
The net debt of Gennex Laboratories Limited is ₹793M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Gennex Laboratories Limited in the live analysis
One click puts Gennex Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
